Therapeutic Virus Production
Therapeutic Virus Production - Related Videos
02:27
Production and Harvesting of Therapeutic Virus-Producing Epithelial Cells
0 Views •
2026
Source: Heidbuechel, J. P., et al. Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo. J. Vis. Exp. (2019).This video demonstrates the process of infecting kidney epithelial cells with genetically engineered viruses for their production and harvesting to study viral replication.
10:49
Estimating Virus Production Rates in Aquatic Systems
0 Views •
Cited by 8 •
2010
The turnover rate of viruses in marine and freshwater systems can be estimated by a reduction and reoccurrence technique. The data allow researchers to infer rates of virus-mediated microbial mortality in aquatic systems.
09:54
Laboratory Scale Production and Purification of a Therapeutic Antibody
0 Views •
Cited by 9 •
2017
This protocol describes the production of a therapeutic antibody in a mammalian expression system. The methods described include preparation of vector DNA, stable transfection and serum-free adaptation of a human embryonic kidney 293 cell line, set up of large scale cultures and purification using affinity chromatography.
03:08
Production of Reporter-Containing Ebola Virus Transcription- and Replication-Competent Virus-Like Particles
0 Views •
2026
Source: Hoenen, T., et al. Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes. J. Vis. Exp. (2014)This video demonstrates how a tetracistronic minigenome plasmid mimicking the Ebola virus genome is transfected into human cells along with helper plasmids. Inside the cells, viral proteins and luciferase are expressed, leading to the assembly and budding of non-pathogenic, replication-competent virus-like...
04:12
Production and Purification of Recombinant Hepatitis B Virus Particles
0 Views •
2026
Source: Nishitsuji, H., et al. Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle. J. Vis. Exp. (2017)This video demonstrates the production and purification of recombinant Hepatitis B virus particles, enabling safe, replication-deficient viral preparations for studying early infection events and for high-throughput antiviral drug screening applications.
FAQs
Host cells provide the environment needed for a defined viral genome to produce or assemble therapeutic particles. Depending on the product, the cells may support virus replication or assemble vector particles for gene delivery. Their biological compatibility with the viral genome directly influences whether production proceeds efficiently and whether the resulting material contains usable therapeutic particles.
Cell culture conditions affect how effectively host cells support replication or particle assembly. Process control helps maintain reproducible production while limiting contaminants and defective particles. Controlling these factors is important because changes in culture performance can alter yield and product quality, making later purification and testing less reliable across production runs.
Viral vectors are produced to deliver therapeutic genes into target cells, whereas oncolytic viruses are designed to target and selectively destroy cancer cells. This difference determines which biological outcome the production process must support. In both cases, the manufactured particles must retain the properties needed for their intended therapeutic or research use.
A typical workflow begins by introducing the defined viral genome into suitable host cells and maintaining conditions that support replication or vector assembly. The material is then harvested, purified, and tested. These stages connect biological production with product preparation, removing or limiting unwanted material before the virus is evaluated for its intended use.
Post-production testing examines identity, potency, purity, and safety. Identity confirms that the product corresponds to the intended virus or vector, while potency addresses its functional therapeutic capability. Purity and safety testing help identify unwanted contaminants or unsuitable material. Together, these measurements determine whether a batch is consistent enough for research or treatment development.
The approach supports gene therapy by supplying vectors that deliver therapeutic genes, and it supports cancer research through oncolytic viruses designed to destroy diseased cells. It also contributes to developing scalable treatments, where consistent yields and controlled quality are necessary for moving from experimental production toward broader therapeutic evaluation.